Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.

We report the use of the steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the management of patients with advanced, hormone resistant, prostatic cancer. Eighteen of 25 patients (72%) showed a subjective response, mainly in the form of pain relief and increased performan...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Davies, J. H., Dowsett, M., Jacobs, S., Coombes, R. C., Hedley, A., Shearer, R. J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 1992
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC1977910/
https://ncbi.nlm.nih.gov/pubmed/1637664
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk